Dr. John Cush RheumNow
8 months 1 week ago
Subcutaneous Anifrolumab in SLE
Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab. https://t.co/EzaqS5q096
Dr. John Cush RheumNow
8 months 1 week ago
The 2025 Rheumatology Year in Review
The year 2025 presented numerous advances in rheumatology and related inflammatory and autoimmune disorders, ranging from several new groundbreaking FDA approvals/indications, drug developments, game-changing guidelines, and practices that https://t.co/71stL3X8my
Dr. John Cush RheumNow
8 months 1 week ago
ANAs and Autoantibodies
https://t.co/AANvCKeAl0 https://t.co/SSPUxMEuLh
Dr. John Cush RheumNow
8 months 1 week ago
Are JAK Inhibitors Better at Pain Relief in RA?
Among rheumatoid arthritis (RA) patients who responded to upadacitinib (Rinvoq) or adalimumab, those receiving upadacitinib had significantly less residual pain with treatment, according to a post hoc analysis of phase III trial https://t.co/QrbwlxIm3d
Dr. John Cush RheumNow
8 months 1 week ago
Review of Restless Legs Syndrome
JAMA has published a full review of RLS - restless leg syndrome - a frequent, but often unrecognized, cause of poor sleep and the resultant hazards of insomnia.
https://t.co/lPSMH3v7xS https://t.co/lbSfeNrfLz
Dr. John Cush RheumNow
8 months 1 week ago
Acupuncture in SpA metanalysis of 35 RCTs (2,591 AS pts) showed statistically significant improvements BASDAI score, BASFI score, ASDAS, VAS score, CRP level, and ESR level. Findings imited by high heterogeneity & the lack of large-scale, high-quality RCTs. https://t.co/gznAiNo0k4
Dr. John Cush RheumNow
8 months 1 week ago
Retrospective real-world study of 87 Behcets dz pts & inital Rx w/ IFX (n 45) or ADA (n 42) (2020 to 2025) & >60% were on AZA. Complete remission achieved in 76% (IFX) vs 79% (ADA) initially, & 89% vs 77% last visit. Same Rx retention but more relapses w/ IFX (38% v 17%) https://t.co/6FiuYe0GI9
Using the long-running, U.S.-based Health and Retirement Study (HRS), which enrolls people age 50 and older, as the data source, Ross Wilkie, PhD, of Keele University in Staffordshire, England, and colleagues estimated that those reporting an arthritis diagnosis could expect just 6.18 more years of being able to work without physical limitations, compared with 11.71 years for those without arthritis.
Dr. John Cush RheumNow
8 months 1 week ago
UCAN CAN-DU study of 181 JIA pts starting biologics. Early Rx w/in 6 mos (n=35) assoc. w/ greater odds of achieving inactive arthritis (83% vs 57% in late starters (>12 mos). For each month of delay increased the odds of future active arthritis (after 6 mos) by 9%.
Due to the complexity of SLE, rheumatology providers should take an active role in assessing reproductive health, providing education on how SLE may affect pregnancy, and taking a collaborative, multidisciplinary approach with the patient’s gynecologist.
Dr. John Cush RheumNow
8 months 1 week ago
Did you know theres a Subcutaneous (SC) rituximab (Hycela)? Its same RTX but combined w/ hyaluronidase, faster 5-7 minute injection Vs hours for IV RTX. FDA approved 2017 for Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL). Give 1st dose IV, then use SC RTX. https://t.co/piQ2ZhAOyf
Dr. Jack Cush reviews the news and reports from the past two weeks on RheumNow.Com
Dr. John Cush RheumNow
8 months 1 week ago
French Retrospective study (2011-22) of 36129 adult psoriasis pts on biologics who recv antibiotics (9366/26% @ baseline, 61% during FU). Abx treatment assoc w/ 12% greater risk biologic D/C (HR 1.12); more for multiple Abx courses (HR 1.29; 95% CI, 1.24-1.35) https://t.co/2Jv5xCibyd
A large, real-world cohort study of rheumatoid arthritis (RA) finds patients treated with biologic and targeted synthetic DMARDs (b/tsDMARDs) do not have an increased risk of cancer. Researchers used 2000–2023 data for RA patients from the BIOBADASER III registry, a multicentre national registry of patients treated with b/tsDMARDs.
